MedTrace Logo

Clinical Significance and Diagnosis of Sarcopenia in Cardiac Patients

NCT04175080 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 190

Last updated 2019-11-22

No results posted yet for this study

Summary

Obesity sarcopenia, characterized by the coexistence of excess fat and muscle mass reduction, may contribute to the pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). The project will examine the impact of selected circulating miRNAs on processes that may form the pathophysiological basis for HFpEF development and obesity sarcopenia in correlation with biochemical markers, echocardiographic assessment and non-invasive assessment of hemodynamic parameters. In addition, the impact of LDL and HDL on these diseases will be assessed. Determinations of selected adipokines and asymmetric dimethylarginine will also be carried out and their effects on the cardiovascular system will be assessed.

Conditions

Sponsors & Collaborators

  • Medical University of Lodz

    lead OTHER

Principal Investigators

  • Agata Bielecka-Dąbrowa, MD, PhD · Department of Hypertension Medical University of Lodz

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2019-08-31
Completion
2019-11-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175080 on ClinicalTrials.gov